– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy...
“ Top-line Phase 1 CSU results expected at year end 2024 “ SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Reports Fourth Quarter and Full Year 2023 Financial Results
Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages AK006 inhibited mast cell activation and reduced mast cell numbers...
“ Data provide insights on the signaling pathways involved with AK006 mast cell inhibition ““ AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells “ SAN...
Allakos halves workforce, drops lead inflammatory program
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the œCompany) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...